HPMA-based polymeric conjugates in anticancer therapeutics

Sarita Rani; Umesh Gupta

doi:10.1016/j.drudis.2020.04.007

HPMA-based polymeric conjugates in anticancer therapeutics

Drug Discov Today. 2020 Jun;25(6):997-1012. doi: 10.1016/j.drudis.2020.04.007. Epub 2020 Apr 22.

Authors

Sarita Rani¹, Umesh Gupta²

Affiliations

¹ Department of Pharmacy, School of Chemical Sciences and Pharmacy, Central University of Rajasthan, Bandarsindri, Ajmer, Rajasthan, 305817, India.
² Department of Pharmacy, School of Chemical Sciences and Pharmacy, Central University of Rajasthan, Bandarsindri, Ajmer, Rajasthan, 305817, India. Electronic address: umeshgupta175@gmail.com.

PMID: 32334073
DOI: 10.1016/j.drudis.2020.04.007

Abstract

Polymer therapeutics has gained prominence due to an attractive structural polymer chemistry and its applications in diseases therapy. In this review, we discussed the development and capabilities of N-(2-hydroxypropyl) methacrylamide (HPMA) and HPMA-drug conjugates in cancer therapy. The design, architecture, and structural properties of HPMA make it a versatile system for the synthesis of polymeric conjugations for biomedical applications. Research suggests that HPMA could be a possible alternative for polymers such polyethylene glycol (PEG) in biomedical applications. Although numerous clinical trials of HPMA-drug conjugates are ongoing, yet no product has been successfully brought to the market. Thus, further research is required to develop HPMA-drug conjugates as successful cancer therapeutics.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Antineoplastic Agents / chemistry*
Antineoplastic Agents / pharmacology*
Drug Carriers / chemistry
Drug Delivery Systems / methods
Humans
Methacrylates / chemistry*
Neoplasms / drug therapy*
Polymers / chemistry*

Substances

Antineoplastic Agents
Drug Carriers
Methacrylates
Polymers
hydroxypropyl methacrylate